This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human PTPRD Protein, His Tag
catalog :
PTD-H52H9
quantity :
1 mg, 100 ug
price :
2500 USD, 420 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
PTD-H52H9
product name :
Human PTPRD Protein, His Tag
quantity :
1 mg, 100 ug
price :
2500 USD, 420 USD
quantity & price :
$420/100ug,$2500/1mg (500ug × 2)
target :
PTPRD
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human PTPRD, His Tag (PTD-H52H9) is expressed from human 293 cells (HEK293). It contains AA Glu 21 - Glu 1265 (Accession # P23468-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human PTPRD, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Receptor-type tyrosine-protein phosphatase delta is an enzyme that is encoded by the PTPRD gene. The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. PTPRD has been shown to interact with PTPRS and liprin-alpha-1. Studies of the similar genes in chick and fly suggest the role of this PTP is in promoting neurite growth, and regulating neurons axon guidance. Multiple tissue specific alternatively spliced transcript variants of this gene have been reported. Mutations in the PTPRD gene are associated with autism, obsessive–compulsive disorder, and breast cancer.
References :
(1)Pulido R., etal., 1995, J Biol Chem., 270 (12): 6722-6728.
(2)Mizuno K., et al., 1993, Mol. Cell Biol., 13 (9): 5513-5523.
(3)Wallace MJ., et al., 1998, Mol. Cell Biol., 18 (5): 2608-2616.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments